drugset / Trial / NCT03181815
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The vast majority of patients with AML will die of the disease, and no standard chemotherapy regimen were defined for patients with relapsed/refractory AML. Previous studies have confirmed the efficacy of cladribine in the treatment of AML, both de novo or relapse/refractory AML. Our previous experience has shown that Cladribine in combination of CAG (G-CSF priming, low dose cytarabine, and aclarubicin) are effective with tolerable toxicity profiling.Thus, this phase 2 clincial trial is going to evaluate the efficacy and safety of cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin (C-CAG) in patients with refractory/relapsed acute myeloid leukemia.
Timeline
- Start
- 2016-01-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 5 mg/m2 | — |
| Background | Aclarubicin | Small molecule | 10 mg | — |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Background | G-CSF | Unknown | 300 ug | — |